Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-676 pembrolizumab plus BCG in high-risk non-muscle invasive bladder cancer
jRCT2031200390Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised trial of pembrolizumab and bcg vaccine in non-muscle-invasive bladder cancer (NMIBC), transitional cell carcinoma of the bladder (TCC) and Bladder cancer in situ (CIS) (5 cohorts), sponsored by Merck & Co. Primary endpoints: Complete response rate and Event-free survival. Started Mar 2021; status: active, not recruiting.
02
Drugs
pembrolizumabbcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)transitional cell carcinoma of the bladder (TCC)Bladder cancer in situ (CIS)
Beyond the preview
Go deeper on jRCT2031200390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200390.